MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

Law firms are recruiting potential lead plaintiffs following Phase 3 results that contradicted MoonLake’s touted Nanobody advantages.

Overview

Notices this week from Rosen, Schall, DJS Law Group, Berger Montague, and Glancy Prongay & Murray urge motions for lead-plaintiff by December 15, 2025.
The putative class covers purchasers of MoonLake common stock from March 10, 2024 through September 29, 2025.
The complaints, filed in federal court, allege violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5.
Plaintiffs say MoonLake overstated sonelokimab’s Nanobody-derived superiority despite sharing IL‑17A and IL‑17F targets with BIMZELX and lacking proven clinical advantage.
MoonLake’s shares fell about 90% on September 29, 2025 after Phase 3 data showed SLK failed to match BIMZELX efficacy, and no class has been certified to date.